Phaseline

Targets › PRKCA

PRKCA (Protein kinase C alpha type): drug programs, companies and trials

1 program from 1 company in 1 trial: 1 Phase 1; Metabolic and endocrine; next expected readout May 2027.

Calcium-activated, phospholipid- and diacylglycerol (DAG)-dependent serine/threonine-protein kinase that is involved in positive and negative regulation of cell proliferation, apoptosis, differentiation, migration and adhesion, tumorigenesis, cardiac hypertrophy, angiogenesis, platelet function and inflammation, by directly phosphorylating targets such as RAF1, BCL2, CSPG4, TNNT2/CTNT, or activating signaling…. (UniProt, P17252)

Open in Phaseline: the race on PRKCA, likelihood bands and readouts

Programs

CompanyDrugTargetsHighest phaseConditionsNext expected readout
AdipoPharmaPATAS Trifluoroacetate
Modulator of ALMS1-PKC alpha interaction
ALMS1, PRKCAPhase 1Type 2 DiabetesMay 2027

Conditions

Type 2 Diabetes (1)

Modalities

small molecule (1)

Companies

AdipoPharma (1)

Related targets

ALMS1 (1)

Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.